Results 151 to 160 of about 65,145,522 (276)

Acute anaphylactic and multiorgan inflammatory effects of Comirnaty in pigs: evidence of spike protein mRNA transfection and paralleling inflammatory cytokine upregulation

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 20, Page 6225-6239, October 2026.
Abstract Background and Purpose Rare but severe adverse events (AEs) associated with mRNA‐lipid nanoparticle (LNP) COVID‐19 vaccines, such as Comirnaty, include anaphylaxis and inflammatory organ disorders, but their underlying mechanisms are poorly understood. We aimed to develop an animal model to study these phenomena.
László Dézsi   +13 more
wiley   +1 more source

Characterization of quasispecies of severe fever with thrombocytopenia syndrome virus

open access: yesJournal of Virology
ABSTRACT Three specific amino acid variations have been identified in the quasispecies of the isolated YG1 strain of severe fever with thrombocytopenia syndrome virus (SFTSV): Gn (Y328H), Gc (R624W), and L (N1891K). The Gn (Y328H) accounted for 26.9% of the viruses in the patient’s blood.
Sithumini M. W. Lokupathirage   +6 more
openaire   +2 more sources

Additional file 1: of Spatial epidemiological determinants of severe fever with thrombocytopenia syndrome in Miyazaki, Japan: a GWLR modeling study

open access: yes, 2019
Datasets of mesh areas with observed cases of severe fever with thrombocytopenia syndrome (SFTS), with altitude and farmland, in Miyazaki, Japan (XLSX 13 ...
Kazuhiro Yasuo (6814157)   +1 more
core   +1 more source

Beyond the Kidney and Lung: Cutaneous and Mucosal Clues to Human Hantavirus Disease

open access: yesInternational Journal of Dermatology, Volume 65, Issue 10, Page 2018-2027, October 2026.
Rodent exposure and aerosolized excreta can lead to hantavirus infection with systemic endothelial injury and capillary leak, resulting in thrombocytopenia and syndromes such as HPS/HCPS and HFRS/NE. Early dermatologic and mucosal findings, including flushing, conjunctival injection, petechiae/purpura, and mucosal bleeding, may provide important clues ...
Giuseppe Gallo   +2 more
wiley   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

open access: yesJournal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Leukocytoclastic Vasculitis Secondary to Severe Fever with Thrombocytopenia Syndrome

open access: yesInternal Medicine
A 75-year-old Japanese woman was admitted to our hospital and diagnosed with hemophagocytic syndrome secondary to severe fever with thrombocytopenia syndrome (SFTS). The patient recovered after steroid treatment and was discharged from the hospital. Two months after the onset of SFTS, the patient revisited our hospital with a fever and palpable purpura
Otsuka, Yohei   +2 more
openaire   +2 more sources

Severe Fever with Thrombocytopenia Syndrome in Japan and Public Health Communication

open access: yes, 2015
A fatal case of severe fever with thrombocytopenia syndrome was reported in Japan in 2013. The ensuing process of public communication offers lessons on how to balance public health needs with patient privacy and highlights the importance of multilateral
Tomoya Saito   +3 more
core   +1 more source

Impact of PD‐1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib‐Based Triple Therapy

open access: yesLiver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background and Aims The optimal sequencing of programmed cell death protein 1 (PD‐1) inhibitors relative to locoregional therapy (LRT) in unresectable hepatocellular carcinoma (uHCC) remains undefined. This study evaluated the impact of PD‐1 inhibitor timing on outcomes in patients receiving hepatic arterial infusion chemotherapy (HAIC) or ...
Jian He   +13 more
wiley   +1 more source

Dordaviprone Maintenance After Allogeneic HCT for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2288-2296, September 2026.
ABSTRACT Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell ...
Vijaya Raj Bhatt   +8 more
wiley   +1 more source

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2297-2310, September 2026.
ABSTRACT Hydroxyurea (HU) is the most widely prescribed disease‐modifying treatment in sickle cell disease (SCD), though treatment responses vary due to metabolism and adherence. We examined HU blood levels and treatment response in patients with homozygous sickle cell disease (HbSS).
Sigrid van der Veen   +26 more
wiley   +1 more source

Home - About - Disclaimer - Privacy